文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

开发基于寡甘露糖修饰的脂质体鼻用疫苗以预防 3 型人副流感病毒。

Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3.

机构信息

Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Kanagawa Japan.

出版信息

Front Microbiol. 2013 Nov 26;4:346. doi: 10.3389/fmicb.2013.00346. eCollection 2013.


DOI:10.3389/fmicb.2013.00346
PMID:24324462
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3840497/
Abstract

Human parainfluenza viruses (HPIVs) are the etiologic agents of lower respiratory infections and pneumonia in infants, young children and immunocompromised hosts. The overarching goal for the prevention of HPIV infection is the development of an effective vaccine against HPIVs. In the present study, we investigated the effectiveness of oligomannose-coated liposomes (OMLs) as an antigen-delivery system in combination with a synthetic double-stranded RNA analog for the induction of mucosal and systematic immunity against HPIV3. Full-length hemagglutinin-neuraminidase (HN) protein was synthesized using the wheat germ cell-free protein production system and then encapsulated into OML to serve as the antigen. Intranasal administration of the HN-filling OML (OML-HN) with the synthetic double-stranded RNA adjuvant, polyriboinosinic-polyribocytidylic acid [poly(I:C)] generated significant viral-specific systemic and mucosal immune responses as evidenced by the prominent induction of serum IgG and nasal wash IgA, respectively. On the other hand, no significant immune responses were observed in mice immunized with OML-HN without the adjuvant. Furthermore, serum from mice immunized with OML-HN plus poly(I:C) significantly suppressed viral infection in cell culture model. Our results provide the first evidence that intranasal co-administration of OML-encapsulated HN with the poly(I:C) adjuvant augments the viral-specific immunity against HPIV3.

摘要

人类副流感病毒(HPIVs)是婴幼儿、儿童和免疫功能低下宿主下呼吸道感染和肺炎的病原体。预防 HPIV 感染的首要目标是开发针对 HPIVs 的有效疫苗。在本研究中,我们研究了寡甘露糖包被的脂质体(OMLs)作为一种抗原传递系统与合成双链 RNA 类似物联合用于诱导针对 HPIV3 的粘膜和系统免疫的效果。全长血凝素神经氨酸酶(HN)蛋白使用小麦胚无细胞蛋白生产系统合成,然后封装到 OML 中作为抗原。用合成双链 RNA 佐剂聚肌胞苷酸[poly(I:C)]鼻内给予填充 HN 的 OML(OML-HN),分别通过明显诱导血清 IgG 和鼻洗液 IgA ,产生了显著的病毒特异性全身和粘膜免疫应答。另一方面,在用佐剂 poly(I:C) 免疫的小鼠中未观察到 OML-HN 引起的显著免疫应答。此外,用 OML-HN 加 poly(I:C)免疫的小鼠的血清在细胞培养模型中显著抑制了病毒感染。我们的结果首次提供了证据表明,鼻内共给予包被有 HN 的 OML 和 poly(I:C) 佐剂增强了针对 HPIV3 的病毒特异性免疫。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de82/3840497/585d6a15d466/fmicb-04-00346-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de82/3840497/44d7adc7da74/fmicb-04-00346-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de82/3840497/c19721a0a3c3/fmicb-04-00346-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de82/3840497/664fbe9af68d/fmicb-04-00346-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de82/3840497/585d6a15d466/fmicb-04-00346-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de82/3840497/44d7adc7da74/fmicb-04-00346-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de82/3840497/c19721a0a3c3/fmicb-04-00346-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de82/3840497/664fbe9af68d/fmicb-04-00346-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de82/3840497/585d6a15d466/fmicb-04-00346-g004.jpg

相似文献

[1]
Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3.

Front Microbiol. 2013-11-26

[2]
A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine.

Vaccine. 2013-10-19

[3]
Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization.

Glycoconj J. 2009-10-9

[4]
Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections.

Vaccine. 2008-6-25

[5]
Vaccination with a human parainfluenza virus type 3 chimeric FHN glycoprotein formulated with a combination adjuvant induces protective immunity.

Vaccine. 2017-11-16

[6]
Requirement of TLR4 signaling for the induction of a Th1 immune response elicited by oligomannose-coated liposomes.

Immunol Lett. 2016-10

[7]
Vaccination with profilin encapsulated in oligomannose-coated liposomes induces significant protective immunity against Toxoplasma gondii.

Vaccine. 2014-2-13

[8]
Immunotherapy with oligomannose-coated liposomes ameliorates allergic symptoms in a murine food allergy model.

Allergy. 2012-3

[9]
A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.

Antiviral Res. 2018-7-30

[10]
Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.

J Virol. 2005-3

引用本文的文献

[1]
Peptides targeting RAB11A-FIP2 complex inhibit HPIV3, RSV, and IAV replication as broad-spectrum antivirals.

Cell Biosci. 2025-4-21

[2]
A robust mouse model of HPIV-3 infection and efficacy of GS-441524 against virus-induced lung pathology.

Nat Commun. 2024-9-5

[3]
Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance.

Vaccines (Basel). 2022-7-14

[4]
Strategies for fighting pandemic virus infections: Integration of virology and drug delivery.

J Control Release. 2022-3

[5]
Nano-Microparticle Platforms in Developing Next-Generation Vaccines.

Vaccines (Basel). 2021-6-5

[6]
Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests.

Cell Rep Med. 2021-6-15

[7]
Exportin-1-Dependent Nuclear Export of DEAD-box Helicase DDX3X is Central to its Role in Antiviral Immunity.

Cells. 2019-9-30

[8]
The Role of Human Parainfluenza Virus Infections in the Immunopathology of the Respiratory Tract.

Curr Allergy Asthma Rep. 2017-3

[9]
Epidemiology of parainfluenza infection in England and Wales, 1998-2013: any evidence of change?

Epidemiol Infect. 2017-4

[10]
Development of Monoclonal Antibody and Diagnostic Test for Middle East Respiratory Syndrome Coronavirus Using Cell-Free Synthesized Nucleocapsid Antigen.

Front Microbiol. 2016-4-20

本文引用的文献

[1]
Oligomannose-coated liposome-entrapped dense granule protein 7 induces protective immune response to Neospora caninum in cattle.

Vaccine. 2013-8-2

[2]
Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.

J Virol. 2013-3-20

[3]
Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.

Vaccine. 2013-3-13

[4]
Liposome-based delivery system for vaccine candidates: constructing an effective formulation.

Nanomedicine (Lond). 2012-12

[5]
The mucosal immune system of the respiratory tract.

Curr Opin Virol. 2012-4-25

[6]
Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.

Vaccine. 2011-12-14

[7]
Detailed genetic analysis of hemagglutinin-neuraminidase glycoprotein gene in human parainfluenza virus type 1 isolates from patients with acute respiratory infection between 2002 and 2009 in Yamagata prefecture, Japan.

Virol J. 2011-12-13

[8]
Mechanism of fusion triggering by human parainfluenza virus type III: communication between viral glycoproteins during entry.

J Biol Chem. 2011-11-22

[9]
Progress in the development of human parainfluenza virus vaccines.

Expert Rev Respir Med. 2011-8

[10]
Progress in respiratory virus vaccine development.

Semin Respir Crit Care Med. 2011-8-19

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索